Tasonermin
Tasonermin (Beromun, Belpharma s.a.) has 1 EU-approved indication in 1 tumour type.
| Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|
| Soft tissue sarcoma1 | |||
None | + melphalan via mild hyperthermic isolated limb perfusion (ILP) | Any line advanced | As an adjunct to surgery for subsequent removal of the tumour to prevent or delay amputation, or in the palliative situation |
Full text of section 4.1 (therapeutic indications)
Beromun is indicated in adults. as an adjunct to surgery for subsequent removal of the tumour so as to prevent or delay amputation, or in the palliative situation, for irresectable soft tissue sarcoma of the limbs, used in combination with melphalan via mild hyperthermic isolated limb perfusion (ILP).
Label history
18 changes to the Beromun label since 1999, none of them to the indications. Newest first, in the words of EMA's record of each procedure.
Changes